aTyr Pharma, Inc. (NASDAQ:ATYR) Stock Has Consensus Price Target of $4.00 According to Analysts

Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) have been assigned a consensus recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $5.00.

A number of analysts have recently commented on the company. Freedom Broker cut aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. Wells Fargo & Company increased their target price on aTyr Pharma from $1.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. Finally, Royal Bank Of Canada lowered their target price on aTyr Pharma to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 6th.

aTyr Pharma Trading Down 8.3%

Shares of NASDAQ ATYR opened at $6.21 on Friday. aTyr Pharma has a 12-month low of $4.07 and a 12-month high of $44.40. The firm’s 50-day simple moving average is $10.61 and its 200 day simple moving average is $23.15.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). The business had revenue of $235.23 million during the quarter, compared to analysts’ expectations of $2.50 million. Research analysts expect that aTyr Pharma will post -22.96 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

A hedge fund recently raised its position in aTyr Pharma stock. Bank of America Corp DE increased its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 303,559 shares of the company’s stock after acquiring an additional 176,859 shares during the period. Bank of America Corp DE owned approximately 0.31% of aTyr Pharma worth $237,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.